Susan Abushakra, MD, Chief Medical Officer at Alzheon, discusses the validity of the amyloid hypothesis in light of the recent Cochrane review that found no clinical benefit of anti-amyloid monoclonal antibodies. A Cochrane systematic review published in April 2026 by Nonino, et al. – examining 17 randomised controlled trials encompassing more than 20,000 participants – […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!